188 related articles for article (PubMed ID: 24771049)
41. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
[TBL] [Abstract][Full Text] [Related]
42. The prognostic value of lymph node ratio in node-positive breast cancer: a Dutch nationwide population-based study.
Dings PJ; Elferink MA; Strobbe LJ; de Wilt JH
Ann Surg Oncol; 2013 Aug; 20(8):2607-14. PubMed ID: 23536053
[TBL] [Abstract][Full Text] [Related]
43. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
44. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
Kassam F; Enright K; Dent R; Dranitsaris G; Myers J; Flynn C; Fralick M; Kumar R; Clemons M
Clin Breast Cancer; 2009 Feb; 9(1):29-33. PubMed ID: 19299237
[TBL] [Abstract][Full Text] [Related]
45. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.
Kim HJ; Kwon H; Lee JW; Kim HJ; Lee SB; Park HS; Sohn G; Lee Y; Koh BS; Yu JH; Son BH; Ahn SH
Breast Cancer Res; 2015 May; 17(1):64. PubMed ID: 25935404
[TBL] [Abstract][Full Text] [Related]
46. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
47. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Zell JA; Tsang WY; Taylor TH; Mehta RS; Anton-Culver H
Breast Cancer Res; 2009; 11(1):R9. PubMed ID: 19228416
[TBL] [Abstract][Full Text] [Related]
48. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.
Solak M; Turkoz FP; Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Sever AR; Altundag K
J BUON; 2015; 20(3):737-45. PubMed ID: 26214625
[TBL] [Abstract][Full Text] [Related]
49. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
50. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Peer PG; Tjan-Heijnen VC
Ann Oncol; 2016 Feb; 27(2):256-62. PubMed ID: 26578730
[TBL] [Abstract][Full Text] [Related]
51. Development of a Prognostic Factor Index Among Women With HR
Vidal GA; Carter GC; Gilligan AM; Saverno K; Zhu YE; Price GL; DeLuca A; Smyth EN; Rybowski S; Huang YJ; Schwartzberg LS
Clin Breast Cancer; 2021 Aug; 21(4):317-328.e7. PubMed ID: 33678566
[TBL] [Abstract][Full Text] [Related]
52. An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients.
Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
Breast; 2015 Oct; 24(5):667-72. PubMed ID: 26346586
[TBL] [Abstract][Full Text] [Related]
53. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study.
Rakha EA; Tan PH; Varga Z; Tse GM; Shaaban AM; Climent F; van Deurzen CH; Purnell D; Dodwell D; Chan T; Ellis IO
Br J Cancer; 2015 Jan; 112(2):283-9. PubMed ID: 25422911
[TBL] [Abstract][Full Text] [Related]
54. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
Andrulis IL; Bull SB; Blackstein ME; Sutherland D; Mak C; Sidlofsky S; Pritzker KP; Hartwick RW; Hanna W; Lickley L; Wilkinson R; Qizilbash A; Ambus U; Lipa M; Weizel H; Katz A; Baida M; Mariz S; Stoik G; Dacamara P; Strongitharm D; Geddie W; McCready D
J Clin Oncol; 1998 Apr; 16(4):1340-9. PubMed ID: 9552035
[TBL] [Abstract][Full Text] [Related]
55. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
56. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
[TBL] [Abstract][Full Text] [Related]
57. Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.
Marshall EM; Bertaut A; Desmoulins I; Darut-Jouve A; Ponnelle T; Poillot ML; Beltjens F; Arveux P
Breast J; 2017 Mar; 23(2):138-145. PubMed ID: 27935232
[TBL] [Abstract][Full Text] [Related]
58. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thezenas S; Jacot W
BMC Cancer; 2016 Jul; 16():428. PubMed ID: 27387327
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients With Multiple Metastatic Sites.
Li N; Hao Y; Xie J; Lin PL; Koo V; Ohashi E; Wu EQ
Clin Ther; 2016 Apr; 38(4):905-17. PubMed ID: 26947172
[TBL] [Abstract][Full Text] [Related]
60. Metastasis-free interval in breast cancer patients: Thirty-year trends and time dependency of prognostic factors. A retrospective analysis based on a single institution experience.
Houzé de l'Aulnoit A; Rogoz B; Pinçon C; Houzé de l'Aulnoit D
Breast; 2018 Feb; 37():80-88. PubMed ID: 29102782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]